News Conference News EAS 2025 Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM Yael L. Maxwell May 08, 2025
News Conference News EAS 2023 High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture Michael O'Riordan May 23, 2023
News Conference News EAS 2022 Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively Michael O'Riordan May 27, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2021 High Ischemic Risk and Bleeding Risk: A Delicate Balance Post-PCI Michael O'Riordan June 08, 2021
News Conference News EAS 2021 For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short Michael O'Riordan June 03, 2021
News Conference News EAS 2019 Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019
News Conference News EAS 2017 Is Atherosclerosis an LDL-Cholesterol or Immune Disease? The Answer May Be Both Yael L. Maxwell April 25, 2017
News Conference News EAS 2016 Nutrition and Physical Activity: The ‘Low-Hanging Fruit’ for Cardiologists Programmed to Prescribe Pills Yael L. Maxwell June 07, 2016
News Conference News EAS 2016 Statin-Associated Muscle Symptoms: Real or ‘Artificial,’ Physicians Should Take Time to Manage Patients Yael L. Maxwell June 01, 2016
News Conference News EAS 2016 Good Fats, Bad Fats, and Sugar: A ‘Big Picture’ Approach Is Warranted With Diet Interventions for Cardiovascular Disease Yael L. Maxwell May 31, 2016